Business Context and Reporting Period
This Form 8-K is a current report filed by Kalaris Therapeutics, Inc. on April 16, 2025, covering events occurring on April 10, 2025, and April 15, 2025. The filing discloses the execution of new employment agreements and amendments for key executive officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
Andrew Oxtoby (President and CEO)
- Agreement Date: April 10, 2025.
- Base Salary: $569,100 annualized.
- Target Bonus: Up to 55% of base salary.
- Severance (Outside Change in Control Window): 12 months of base salary and health premium coverage upon termination without cause or for good reason.
- Severance (Within Change in Control Window): 18 months of base salary, 150% of Target Bonus, 18 months of health premium coverage, and full acceleration of time-based equity awards.
Brett Hagen (SVP and Chief Accounting Officer)
- Agreement Date: April 15, 2025 (Amendment to December 17, 2024 offer letter).
- Severance (Outside Change in Control Window): 9 months of base salary and health premium coverage upon termination without cause or for good reason.
- Severance (Within Change in Control Window): 12 months of base salary, 100% of Target Bonus, 12 months of health premium coverage, and full acceleration of time-based equity awards.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the potential for significant severance payouts and equity acceleration in the event of a "change in control" of the Company.
Investor Verification Checklist
- Verify the total potential cash and equity liability for CEO Andrew Oxtoby in a change-in-control scenario (18 months salary + 150% bonus + equity).
- Confirm the specific definitions of "cause" and "good reason" in the attached Exhibit 10.1 and 10.2 to understand termination triggers.
- Review the Company's current cash position in the most recent 10-Q or 10-K to assess the ability to fund these severance obligations if triggered.
- Check for any other pending executive agreements that may not be detailed in this specific 8-K.